NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 2)
key details
| Value | £424,035,364 |
|---|---|
| Status | complete |
| Category (CPV) | 33600000 |
| Deadline | 23 Nov 2023 |
| Contract start | 1 Jun 2024 |
| Contract end | 31 May 2027 |
| Procedure | open |
| SME suitable | Yes |
| OCID | ocds-b5fd17-473f438e-1571-48a1-aa1d-5a4342588eda |
Awards (63)
This procurement was awarded to 63 suppliers. Values shown are per-award; the notice total is £424,035,364.
| Supplier | Value | Date | Status |
|---|---|---|---|
| Accord-UK Ltd shared | £1 | 4 Mar 2024 | active |
| AOP Orphan Ltd shared | £1 | 4 Mar 2024 | active |
| Arcadia Pharma Ltd T/A Arcadia Medical shared | £1 | 4 Mar 2024 | active |
| Ascend Laboratories UK Ltd shared | £1 | 4 Mar 2024 | active |
| Aspen Pharmacare UK Limited shared | £1 | 4 Mar 2024 | active |
| Baxter Healthcare Ltd shared | £1 | 4 Mar 2024 | active |
| Bayer Plc shared | £1 | 4 Mar 2024 | active |
| Beaumont Pharma Ltd shared | £1 | 4 Mar 2024 | active |
| Bristol Laboratories Limited shared | £1 | 4 Mar 2024 | active |
| Brown & Burk UK Ltd shared | £1 | 4 Mar 2024 | active |
| Chiesi Limited shared | £1 | 4 Mar 2024 | active |
| Cipla shared | £1 | 4 Mar 2024 | active |
| Clydesdale Pharma ltd shared | £1 | 4 Mar 2024 | active |
| Correvio GmbH shared | £1 | 4 Mar 2024 | active |
| Crescent Pharma Ltd shared | £1 | 4 Mar 2024 | active |
| Derma UK shared | £1 | 4 Mar 2024 | active |
| Dr Falk Pharma UK Ltd shared | £1 | 4 Mar 2024 | active |
| Drugsrus Ltd shared | £1 | 4 Mar 2024 | active |
| Eramol (UK) Ltd shared | £1 | 4 Mar 2024 | active |
| Evolan Pharma shared | £1 | 4 Mar 2024 | active |
| Ferring Pharmaceuticals Ltd shared | £1 | 4 Mar 2024 | active |
| Focus Pharmaceuticals Ltd shared | £1 | 4 Mar 2024 | active |
| Galen Limited shared | £1 | 4 Mar 2024 | active |
| Galvany Pharma Ltd shared | £1 | 4 Mar 2024 | active |
| Genesis Pharmaceuticals Ltd shared | £1 | 4 Mar 2024 | active |
| JCSH Pharma Ltd shared | £1 | 4 Mar 2024 | active |
| Krka UK ltd shared | £1 | 4 Mar 2024 | active |
| Kyowa Kirin Ltd shared | £1 | 4 Mar 2024 | active |
| LogixX Pharma Ltd shared | £1 | 4 Mar 2024 | active |
| Lundbeck Limited shared | £1 | 4 Mar 2024 | active |
| Lupin Healthcare (UK) Limited shared | £1 | 4 Mar 2024 | active |
| Macure Pharma ApS shared | £1 | 4 Mar 2024 | active |
| Manx Healthcare Ltd shared | £1 | 4 Mar 2024 | active |
| Medley Pharma Ltd shared | £1 | 4 Mar 2024 | active |
| MSN Laboratories Europe Limited shared | £1 | 4 Mar 2024 | active |
| Necessity Supplies Limited shared | £1 | 4 Mar 2024 | active |
| Neon Healthcare Ltd shared | £1 | 4 Mar 2024 | active |
| Norgine Pharmaceuticals Limited shared | £1 | 4 Mar 2024 | active |
| Oralieve UK Ltd shared | £1 | 4 Mar 2024 | active |
| Orion Pharma (UK) Ltd shared | £1 | 4 Mar 2024 | active |
| Phoenix Lab shared | £1 | 4 Mar 2024 | active |
| P M Pharma shared | £1 | 4 Mar 2024 | active |
| Reckitt Benckiser shared | £1 | 4 Mar 2024 | active |
| Recordati Pharmaceuticals Ltd shared | £1 | 4 Mar 2024 | active |
| Reig Jofre UK limited shared | £1 | 4 Mar 2024 | active |
| Relonchem Ltd shared | £1 | 4 Mar 2024 | active |
| Rivopharm UK Ltd shared | £1 | 4 Mar 2024 | active |
| RPH Pharmaceuticals AB shared | £1 | 4 Mar 2024 | active |
| Scope Ophthalmics shared | £1 | 4 Mar 2024 | active |
| Stirling Anglian Pharmaceuticals Ltd shared | £1 | 4 Mar 2024 | active |
| Strandhaven Ltd t/a Somex Pharma shared | £1 | 4 Mar 2024 | active |
| Strides Pharma Uk LTD shared | £1 | 4 Mar 2024 | active |
| Synchrony shared | £1 | 4 Mar 2024 | active |
| Syri Limited (T/A Thame Laboratories) shared | £1 | 4 Mar 2024 | active |
| Takeda UK Ltd shared | £1 | 4 Mar 2024 | active |
| Tetris Pharma Lts shared | £1 | 4 Mar 2024 | active |
| Thea Pharmaceuticals Limited shared | £1 | 4 Mar 2024 | active |
| Tillomed Laboratories ltd shared | £1 | 4 Mar 2024 | active |
| Torrent Pharma UK Ltd shared | £1 | 4 Mar 2024 | active |
| Typharm Ltd shared | £1 | 4 Mar 2024 | active |
| Uni Health Distribution Ltd shared | £1 | 4 Mar 2024 | active |
| Vantage Pharmaceuticals Ltd shared | £1 | 4 Mar 2024 | active |
| Waymade PLC shared | £1 | 4 Mar 2024 | active |
description
Invitation to offer for NHS National Generic Pharmaceuticals - Wave 14c Offer reference number: CM/PHG/22/5672
Period of framework agreement: The total maximum duration of the framework agreement to be no more than 36 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 48 months.
Potential periods of call-offs under the framework agreement: Orals (plus non-parenteral) Products: All Regions (CESW/LSNE/NWLN):01/06/2024 to 31/05/2027 (36 Months) Hospital Only Products: DLS & DNE: 01/06/2024 to 31/05/2026(24 months) Hospital Only Products(Housekeeping): DLN & DNW: 01/06/2024 to 31/01/2025(8 months) DCE & DSW: 01/06/2024 to 30/09/2025(16 months)
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 14 May 2024 | Award (award) | · | c3b17fe3-6ef4-4a0a-a5ef-4a4939328e53-750815 |
more from NHS England
- Urgent Award - haematological screening · £16,202 · 29 Jul 2026
- HSCN-AWS Connectivity Service for Spine · £228,060 · 29 Jul 2026
- Incentive Voucher Provider · £60,000 · 29 Jul 2026
- CRM for NHSE participant/candidate data 26-27 · £56,640 · 28 Jul 2026
- Wayfinder and First Contact Digital Clinical Support 2026-27 · £748,000 · 23 Jul 2026
- Support Services for PPM application · £860,000 · 22 Jul 2026
- Digital Maturity Assessment · 21 Jul 2026
- Integrated Healthcare Services to Haslar Immigration Removal Centre (IRC) · £19,052,186 · 13 Jul 2026
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.